Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

The Leukemia & Lymphoma Society will be kicking off its 2015 Light The Night Walk campaign throughout Northern California with the Napa Valley Walk on September 26, 2015 at 5 p.m. PT at Veterans Memorial Park.

25 Aug 2015

Researchers identify strategy to prevent adenoviruses from multiplying and causing sickness in humans

Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.

21 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern Medical Center researchers, in conjunction with NASA, will take four volunteer cancer patients on a zero-gravity ride into the upper atmosphere to study why zero-gravity conditions on the International Space Station sometimes affect the vision of astronauts staying there for extended periods.

20 Aug 2015

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

Isagenix International concludes annual event, raises funds for children's charity organization

Isagenix International, a global health and wellness company, ended its annual Celebration 2015 Breakthrough event in San Diego today by raising more than $565,000 for Make-A-Wish® through fundraising and generous Associate and corporate pledges.

19 Aug 2015

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

17 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

14 Aug 2015

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Cord Blood America, Inc. today announced financial results for the second quarter ended June 30, 2015.

14 Aug 2015

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia.

13 Aug 2015

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.

11 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers.

3 Aug 2015

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.

31 Jul 2015

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Acute lymphoblastic leukemia (ALL) leukemia is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies. Now, an international team of scientists from Berlin, Düsseldorf, Hannover, Heidelberg, Kiel, and Zurich have succeeded in decoding the molecular characteristics of an as yet incurable subtype of leukemia, paving the way for new therapeutic approaches.

30 Jul 2015

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies.

30 Jul 2015

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

Leukemia News and Research

Further Reading

Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

Researchers identify strategy to prevent adenoviruses from multiplying and causing sickness in humans

DelMar closes on $2.6 million registered direct placement

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

Isagenix International concludes annual event, raises funds for children's charity organization

CML survey reveals patient TKI adherence, disease anxiety

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

CML survey reveals patient TKI adherence, disease anxiety

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Newly developed big data technique may have significant impact on health care

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

Researchers create new cell screening method for immunotherapy cancer treatments

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News